AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04012931
Drug: ARV Background Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
Trial: NCT01517854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical to Revatio (sildenafil citrate) three times a day
Trial: NCT03427944
Drug: Calcium Dobesilate group
RxNorm normalized name: calcium dobesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
Trial: NCT03427944
Drug: Conventional Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment were used to treat patients with chronic renal failure.
Trial: NCT00431912
Drug: APO866
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
Trial: NCT03851250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomised to receive placebo will take it in addition to their regular asthma medication.
Trial: NCT04388878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo
Trial: NCT01206062
Drug: Standard control of SBP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Trial: NCT02244216
Drug: Berotec® N 100 µg Metered-dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00823628
Drug: contrast agent (iopromide)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coronary angiography using the allocated contrast agent
Trial: NCT00823628
Drug: contrast agent (iodixanol)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coronary angiography using the allocated contrast agent
Trial: NCT04261166
Drug: A5
RxNorm normalized name: A5MP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
Trial: NCT01692717
Drug: Hydrochlorothiazide + Losartan
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg + 50 mg
Trial: NCT01692717
Drug: Hydrochlorothiazide + Losartan + Atorvastatin
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg + 50 mg + 10 mg
Trial: NCT03190005
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no medication, healthy subjects.
Trial: NCT04298918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral placebo in combination with trastuzumab emtansine.
Trial: NCT03235739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching oral placebo
Trial: NCT04319575
Drug: root canal treatment and intracanal medicament
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks.
Trial: NCT03006705
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Trial: NCT03006705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Trial: NCT02211729
Drug: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
Trial: NCT02211729
Drug: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
Trial: NCT00081848
Drug: rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00081848
Drug: rF-CEA(6D)/TRICOM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00081848
Drug: Recombinant Fowlpox-GM-CSF
RxNorm normalized name: recombinant human GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00081848
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02847650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03306394
Drug: Trifluridine/Tipiracil hydrochloride (S95005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05995288
Drug: Homeopathic Globule
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic globules were administered after careful anamnesis
Trial: NCT03448068
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care
Trial: NCT02711449
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
Trial: NCT00825500
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato placebo (0 mg)
Trial: NCT02703363
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00621699
Drug: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Trial: NCT00621699
Drug: 1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
Trial: NCT01528111
Drug: LX7101 (0.125%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 0.125% LX7101
Trial: NCT01528111
Drug: LX7101 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive vehicle
Trial: NCT03844984
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive normal saline 10 mL
Trial: NCT02703363
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02703363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02605187
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600mg po q6h
Trial: NCT02605187
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650mg po q6h
Trial: NCT02159729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Trial: NCT00791856
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Trial: NCT00791856
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Trial: NCT03535896
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
Trial: NCT00875030
Drug: Arsuamoon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose 50 mg arsuamoon tablet
Trial: NCT00834522
Drug: Kytril® 1 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1 mg, single dose non-fasting
Trial: NCT00905346
Drug: Topamax® 25 mg Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topamax® Capsule 2 x 25 mg
Trial: NCT01437787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT03703102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00428142
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m2 day 1
Trial: NCT01834014
Drug: l-LV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT00330382
Drug: Bowman-Birk inhibitor concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02111161
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of Saline 0.9% (250 ml)
Trial: NCT04585464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally as a single dose or once daily
Trial: NCT04086823
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection to the submental fat area
Trial: NCT04086823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01245582
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT00711620
Drug: Thymosin alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Trial: NCT02192203
Drug: Diclofenac + Menthol Gel
RxNorm normalized name: diclofenac / lidocaine / menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diclofenac, 3% menthol
Trial: NCT02192203
Drug: Diclofenac Only Gel
RxNorm normalized name: diclofenac Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diclofenac, 0.09% menthol
Trial: NCT03462576
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo versus emricasan in Conatus NASH treatment trial
Trial: NCT02556450
Drug: Spironolacton
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Spironolacton 25 mg per day
Trial: NCT02092012
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ıv 50 mg dexketoprofen trometamol after anaesthesia induction
Trial: NCT01106170
Drug: Provex CV
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dietary supplement, 2 capsules per day by mouth
Trial: NCT03513731
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection into the facet joint
Trial: NCT00442780
Drug: BIIB014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol
Trial: NCT00442780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
Trial: NCT01826253
Drug: hydroxyethylstarch 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
Trial: NCT02973685
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin,leucovorin and 5-FU
Trial: NCT02973685
Drug: TACE Drug Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
Trial: NCT01433497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01816997
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
Trial: NCT01816997
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
Trial: NCT00752297
Drug: Preservative-free Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Trial: NCT00752297
Drug: Mentor Purified Toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
Trial: NCT00053417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 15 weeks
Trial: NCT01114048
Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1\~28 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D 1\~4, 15-18 Repeated every 28 days~2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~   * Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration
Trial: NCT03848286
Drug: KL-A167 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Trial: NCT02494479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill designed to match Purisol tablet
Trial: NCT00092729
Drug: etoricoxib (MK0663)
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Trial: NCT00092729
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Trial: NCT00092729
Drug: Comparator: naproxen sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Trial: NCT03015532
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (bupivacaine/meloxicam), via instillation
Trial: NCT03015532
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo via injection
Trial: NCT02184195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Match Olaparib 100mg placebo
Trial: NCT02184195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Match Olaparib 150mg placebo
Trial: NCT02354222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01708603
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered SC
Trial: NCT01232647
Drug: Phylloquinone
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg daily of vitamin K1
Trial: NCT01232647
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo vitamin K1 and placebo MK4 given daily for 18 months
Trial: NCT03430869
Drug: F-18 AV-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
Trial: NCT03762369
Drug: Placebo of CKD-351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT03762369
Drug: Placebo of CKD-351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day
Trial: NCT03762369
Drug: Placebo of D930
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times a day
Trial: NCT02943564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Trial: NCT00869180
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical diclofenac patch applied once daily to area of pain
Trial: NCT02308982
Drug: Immunoglobulins, Intravenous (Privigen)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00870402
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg per day for 9 months
Trial: NCT00870402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet per day for nine months
Trial: NCT00787462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Trial: NCT02005419
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.